vs

Side-by-side financial comparison of Beachbody Company, Inc. (BODI) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $55.5M, roughly 1.4× Beachbody Company, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -35.7%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $4.3M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -32.0%).

The Beachbody Company is a publicly traded American fitness and health company based in El Segundo, California. It sells fitness programs, nutrition, and supplements. Founded in 1998, it is known for its fitness programs P90X and Insanity.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

BODI vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.4× larger
PBYI
$75.5M
$55.5M
BODI
Growing faster (revenue YoY)
PBYI
PBYI
+63.4% gap
PBYI
27.7%
-35.7%
BODI
More free cash flow
PBYI
PBYI
$10.1M more FCF
PBYI
$14.4M
$4.3M
BODI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-32.0%
BODI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BODI
BODI
PBYI
PBYI
Revenue
$55.5M
$75.5M
Net Profit
$5.2M
Gross Margin
74.5%
69.3%
Operating Margin
14.7%
22.7%
Net Margin
9.4%
Revenue YoY
-35.7%
27.7%
Net Profit YoY
115.1%
EPS (diluted)
$0.77
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BODI
BODI
PBYI
PBYI
Q4 25
$55.5M
$75.5M
Q3 25
$59.9M
$54.5M
Q2 25
$63.9M
$52.4M
Q1 25
$72.4M
$46.0M
Q4 24
$86.4M
$59.1M
Q3 24
$102.2M
$80.5M
Q2 24
$110.2M
$47.1M
Q1 24
$120.0M
$43.8M
Net Profit
BODI
BODI
PBYI
PBYI
Q4 25
$5.2M
Q3 25
$3.6M
$8.8M
Q2 25
$-5.9M
$5.9M
Q1 25
$-5.7M
$3.0M
Q4 24
$-34.6M
Q3 24
$-12.0M
$20.3M
Q2 24
$-10.9M
$-4.5M
Q1 24
$-14.2M
$-4.8M
Gross Margin
BODI
BODI
PBYI
PBYI
Q4 25
74.5%
69.3%
Q3 25
74.6%
77.7%
Q2 25
72.3%
76.5%
Q1 25
71.2%
77.1%
Q4 24
70.5%
76.4%
Q3 24
67.3%
63.9%
Q2 24
69.3%
77.4%
Q1 24
67.7%
75.5%
Operating Margin
BODI
BODI
PBYI
PBYI
Q4 25
14.7%
22.7%
Q3 25
8.3%
17.6%
Q2 25
-6.2%
12.7%
Q1 25
-5.1%
8.7%
Q4 24
-38.1%
22.6%
Q3 24
-12.7%
27.4%
Q2 24
-8.6%
-4.6%
Q1 24
-9.0%
-5.3%
Net Margin
BODI
BODI
PBYI
PBYI
Q4 25
9.4%
Q3 25
6.0%
16.2%
Q2 25
-9.2%
11.2%
Q1 25
-7.9%
6.5%
Q4 24
-40.0%
Q3 24
-11.7%
25.2%
Q2 24
-9.9%
-9.6%
Q1 24
-11.8%
-11.0%
EPS (diluted)
BODI
BODI
PBYI
PBYI
Q4 25
$0.77
$0.26
Q3 25
$0.51
$0.17
Q2 25
$-0.85
$0.12
Q1 25
$-0.84
$0.06
Q4 24
$-5.07
$0.40
Q3 24
$-1.75
$0.41
Q2 24
$-1.59
$-0.09
Q1 24
$-2.10
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BODI
BODI
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$39.0M
$97.5M
Total DebtLower is stronger
$25.0M
$22.7M
Stockholders' EquityBook value
$31.3M
$130.3M
Total Assets
$147.0M
$216.3M
Debt / EquityLower = less leverage
0.80×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BODI
BODI
PBYI
PBYI
Q4 25
$39.0M
$97.5M
Q3 25
$33.9M
$94.4M
Q2 25
$25.6M
$96.0M
Q1 25
$18.1M
$93.2M
Q4 24
$20.2M
$101.0M
Q3 24
$32.3M
$96.7M
Q2 24
$32.3M
$96.8M
Q1 24
$38.9M
$107.2M
Total Debt
BODI
BODI
PBYI
PBYI
Q4 25
$25.0M
$22.7M
Q3 25
$25.0M
$34.0M
Q2 25
$25.0M
$45.3M
Q1 25
$56.7M
Q4 24
$21.6M
$68.0M
Q3 24
$25.2M
$79.3M
Q2 24
$24.5M
$90.7M
Q1 24
$28.3M
$102.0M
Stockholders' Equity
BODI
BODI
PBYI
PBYI
Q4 25
$31.3M
$130.3M
Q3 25
$24.7M
$115.3M
Q2 25
$20.2M
$104.7M
Q1 25
$24.0M
$97.1M
Q4 24
$28.2M
$92.1M
Q3 24
$58.4M
$71.1M
Q2 24
$66.8M
$48.5M
Q1 24
$72.7M
$51.0M
Total Assets
BODI
BODI
PBYI
PBYI
Q4 25
$147.0M
$216.3M
Q3 25
$146.4M
$202.9M
Q2 25
$145.9M
$194.9M
Q1 25
$152.5M
$196.2M
Q4 24
$174.6M
$213.3M
Q3 24
$225.5M
$220.7M
Q2 24
$245.0M
$205.0M
Q1 24
$263.0M
$214.1M
Debt / Equity
BODI
BODI
PBYI
PBYI
Q4 25
0.80×
0.17×
Q3 25
1.01×
0.30×
Q2 25
1.24×
0.43×
Q1 25
0.58×
Q4 24
0.77×
0.74×
Q3 24
0.43×
1.12×
Q2 24
0.37×
1.87×
Q1 24
0.39×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BODI
BODI
PBYI
PBYI
Operating Cash FlowLast quarter
$5.0M
$14.4M
Free Cash FlowOCF − Capex
$4.3M
$14.4M
FCF MarginFCF / Revenue
7.7%
19.1%
Capex IntensityCapex / Revenue
1.3%
0.0%
Cash ConversionOCF / Net Profit
0.95×
TTM Free Cash FlowTrailing 4 quarters
$17.4M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BODI
BODI
PBYI
PBYI
Q4 25
$5.0M
$14.4M
Q3 25
$10.2M
$9.7M
Q2 25
$4.2M
$14.1M
Q1 25
$2.3M
$3.6M
Q4 24
$-6.7M
$15.6M
Q3 24
$1.1M
$11.0M
Q2 24
$-925.0K
$1.0M
Q1 24
$9.1M
$11.2M
Free Cash Flow
BODI
BODI
PBYI
PBYI
Q4 25
$4.3M
$14.4M
Q3 25
$9.0M
$9.7M
Q2 25
$2.4M
$14.1M
Q1 25
$1.6M
$3.6M
Q4 24
$-7.3M
$15.6M
Q3 24
$53.0K
$11.0M
Q2 24
$-2.2M
$1.0M
Q1 24
$7.4M
FCF Margin
BODI
BODI
PBYI
PBYI
Q4 25
7.7%
19.1%
Q3 25
15.0%
17.7%
Q2 25
3.8%
26.8%
Q1 25
2.3%
7.7%
Q4 24
-8.4%
26.4%
Q3 24
0.1%
13.7%
Q2 24
-2.0%
2.1%
Q1 24
6.2%
Capex Intensity
BODI
BODI
PBYI
PBYI
Q4 25
1.3%
0.0%
Q3 25
2.0%
0.0%
Q2 25
2.8%
0.0%
Q1 25
1.0%
0.1%
Q4 24
0.7%
0.0%
Q3 24
1.0%
0.0%
Q2 24
1.1%
0.0%
Q1 24
1.4%
0.0%
Cash Conversion
BODI
BODI
PBYI
PBYI
Q4 25
0.95×
Q3 25
2.85×
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BODI
BODI

Digital$34.3M62%
Nutrition And Other$21.2M38%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons